(Q47771132)

5 February 2018

title

Intravitreous injection of AAV2-sFLT01 in patients with advanced neovascular age-related macular degeneration: a phase 1, open-label trial (English)

1 reference

5 February 2018

main subject

phase I clinical trial

0 references

1 reference

Jeffrey S Heier

1

1 reference

5 February 2018

Saleema Kherani

2

1 reference

5 February 2018

Shilpa Desai

3

1 reference

5 February 2018

Pravin Dugel

4

1 reference

5 February 2018

Shalesh Kaushal

5

1 reference

5 February 2018

Seng H Cheng

6

1 reference

5 February 2018

Cheryl Delacono

7

1 reference

5 February 2018

Annie Purvis

8

1 reference

5 February 2018

Susan Richards

9

1 reference

5 February 2018

Annaig Le-Halpere

10

1 reference

5 February 2018

John Connelly

11

1 reference

5 February 2018

Samuel C Wadsworth

12

1 reference

5 February 2018

Rafael Varona

13

1 reference

5 February 2018

Ronald Buggage

14

1 reference

5 February 2018

Abraham Scaria

15

1 reference

5 February 2018

Peter A Campochiaro

16

1 reference

5 February 2018

language of work or name

English

0 references

publication date

16 May 2017

1 reference

5 February 2018

published in

The Lancet

1 reference

5 February 2018

volume

390

1 reference

5 February 2018

issue

10089

1 reference

5 February 2018

page(s)

50-61

1 reference

5 February 2018

Ranibizumab for neovascular age-related macular degeneration

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2817%2930979-0

7 January 2021

HORIZON: an open-label extension trial of ranibizumab for choroidal neovascularization secondary to age-related macular degeneration

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2817%2930979-0

7 January 2021

Ranibizumab and bevacizumab for treatment of neovascular age-related macular degeneration: two-year results

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2817%2930979-0

7 January 2021

Experimental subretinal neovascularization is inhibited by adenovirus-mediated soluble VEGF/flt-1 receptor gene transfection: a role of VEGF and possible treatment for SRN in age-related macular degeneration

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2817%2930979-0

7 January 2021

Periocular injection of an adenoviral vector encoding pigment epithelium-derived factor inhibits choroidal neovascularization

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2817%2930979-0

7 January 2021

Marked inhibition of retinal neovascularization in rats following soluble-flt-1 gene transfer

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2817%2930979-0

7 January 2021

Inhibition of retinal neovascularisation by gene transfer of soluble VEGF receptor sFlt-1.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2817%2930979-0

7 January 2021

Long-term evaluation of AAV-mediated sFlt-1 gene therapy for ocular neovascularization in mice and monkeys

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2817%2930979-0

7 January 2021

Gene therapy using adeno-associated virus vectors

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2817%2930979-0

7 January 2021

Adeno-associated virus-vectored gene therapy for retinal disease

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2817%2930979-0

7 January 2021

Evaluation of AAV-mediated expression of Chop2-GFP in the marmoset retina

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2817%2930979-0

7 January 2021

Intravitreal injection of AAV2 transduces macaque inner retina

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2817%2930979-0

7 January 2021

Novel anti-VEGF chimeric molecules delivered by AAV vectors for inhibition of retinal neovascularization.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2817%2930979-0

7 January 2021

Inhibition of choroidal neovascularization in a nonhuman primate model by intravitreal administration of an AAV2 vector expressing a novel anti-VEGF molecule

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2817%2930979-0

7 January 2021

Preclinical safety evaluation of AAV2-sFLT01- a gene therapy for age-related macular degeneration

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2817%2930979-0

7 January 2021

Photocoagulation for Diabetic Macular Edema

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2817%2930979-0

7 January 2021

Clinical features of drusenoid pigment epithelial detachment in age related macular degeneration

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2817%2930979-0

7 January 2021

Natural history of drusenoid pigment epithelial detachment in age-related macular degeneration: Age-Related Eye Disease Study Report No. 28.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2817%2930979-0

7 January 2021

Retinal pigment epithelial detachments in the elderly: classification and outcome

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2817%2930979-0

7 January 2021

Gene therapy with recombinant adeno-associated vectors for neovascular age-related macular degeneration: 1 year follow-up of a phase 1 randomised clinical trial

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2817%2930979-0

7 January 2021

Antibody neutralization poses a barrier to intravitreal adeno-associated viral vector gene delivery to non-human primates

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2817%2930979-0

7 January 2021

AAV2 gene therapy readministration in three adults with congenital blindness.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2817%2930979-0

7 January 2021

Phase 2a Randomized Clinical Trial: Safety and Post Hoc Analysis of Subretinal rAAV.sFLT-1 for Wet Age-related Macular Degeneration

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2817%2930979-0

7 January 2021

Safety and efficacy of gene transfer for Leber's congenital amaurosis

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2817%2930979-0

7 January 2021

Effect of gene therapy on visual function in Leber's congenital amaurosis

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2817%2930979-0

7 January 2021

Human gene therapy for RPE65 isomerase deficiency activates the retinoid cycle of vision but with slow rod kinetics

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2817%2930979-0

7 January 2021

Retinal gene therapy in patients with choroideremia: initial findings from a phase 1/2 clinical trial.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2817%2930979-0

7 January 2021

Adenoviral vector-delivered pigment epithelium-derived factor for neovascular age-related macular degeneration: results of a phase I clinical trial

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2817%2930979-0

7 January 2021

10.1016/S0140-6736(17)30979-0

Identifiers

DOI

1 reference

5 February 2018

1 reference

5 February 2018